New series of 1,5-disubstituted tetrazoles were designed and synthesized.
In vitro bioassay data of the novel azoles as COX-1/COX-2 inhibitors were reported.
Docking studies in the active site of COX-1/2 were conducted for selected azoles.
Linker’s length/CH2 spacer controlled the azoles selectivity/potency for COX-1/2.
Docking and bioassay studies proved the importance of the structural modifications.